Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib and Atezolizumab in Advanced Non-Small Cell Lung Cancer
NCT06616623Phase 1Suspended
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vismodegib and atezolizumab in non-small cell lung cancer (NSCLC). Primary endpoints: Incidence of adverse events up to 2 years and Incidence of dose limiting toxicity. Started Dec 2024; status: suspended.
02
Drugs
vismodegibatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06616623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616623.